Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Carlsson

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
BJU International|February 6, 2010
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trialSender Herschorn, Steven Swift, Zhonghong Guan, et al.
Drug Discovery Today|November 3, 2015
Repurposing historical control clinical trial data to provide safety contextPrakash Bhuyan, Jigar Desai, Matthew St Louis, et al.
The Journal of Pediatrics|April 17, 2018
Efficacy of Growth Hormone Treatment in Children with Type 1 Diabetes Mellitus and Growth Hormone Deficiency-An Analysis of KIGS DataWalter Bonfig, Anders Lindberg, Martin Carlsson, et al.
The Journal of Urology|July 22, 2008
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptomsEric S Rovner, Karl Kreder, David O Sussman, et al.
The Journal of Pediatrics|June 23, 2019
Near Adult Height in Girls with Turner Syndrome Treated with Growth Hormone Following Either Induced or Spontaneous PubertyRoberto Lanes, Anders Lindberg, Martin Carlsson, et al.
Age and Ageing|January 7, 2017
A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or olderAdrian Wagg, Daniel Arumi, Sender Herschorn, et al.
The Journal of Urology|November 20, 2012
Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgencyJeffrey P Weiss, Zhanna Jumadilova, Theodore M Johnson, et al.
Nutrients|November 16, 2016
Older Swedish Adults with High Self-Perceived Health Show Optimal 25-Hydroxyvitamin D Levels Whereas Vitamin D Status Is Low in Patients with High Disease BurdenMartin Carlsson, Pär Wanby, Lars Brudin, et al.
Journal of Cardiac Failure|June 23, 2024
Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)Pablo Garcia-Pavia, Arnt V Kristen, Brian Drachman, et al.
Current Medical Research and Opinion|August 1, 2017
Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptomsLars Grenabo, Sender Herschorn, Steven A Kaplan, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
BJU International|February 6, 2010
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trialSender Herschorn, Steven Swift, Zhonghong Guan, et al.
Drug Discovery Today|November 3, 2015
Repurposing historical control clinical trial data to provide safety contextPrakash Bhuyan, Jigar Desai, Matthew St Louis, et al.
The Journal of Pediatrics|April 17, 2018
Efficacy of Growth Hormone Treatment in Children with Type 1 Diabetes Mellitus and Growth Hormone Deficiency-An Analysis of KIGS DataWalter Bonfig, Anders Lindberg, Martin Carlsson, et al.
The Journal of Urology|July 22, 2008
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptomsEric S Rovner, Karl Kreder, David O Sussman, et al.
The Journal of Pediatrics|June 23, 2019
Near Adult Height in Girls with Turner Syndrome Treated with Growth Hormone Following Either Induced or Spontaneous PubertyRoberto Lanes, Anders Lindberg, Martin Carlsson, et al.
Age and Ageing|January 7, 2017
A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or olderAdrian Wagg, Daniel Arumi, Sender Herschorn, et al.
The Journal of Urology|November 20, 2012
Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgencyJeffrey P Weiss, Zhanna Jumadilova, Theodore M Johnson, et al.
Nutrients|November 16, 2016
Older Swedish Adults with High Self-Perceived Health Show Optimal 25-Hydroxyvitamin D Levels Whereas Vitamin D Status Is Low in Patients with High Disease BurdenMartin Carlsson, Pär Wanby, Lars Brudin, et al.
Journal of Cardiac Failure|June 23, 2024
Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)Pablo Garcia-Pavia, Arnt V Kristen, Brian Drachman, et al.
Current Medical Research and Opinion|August 1, 2017
Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptomsLars Grenabo, Sender Herschorn, Steven A Kaplan, et al.
Pageof 6